Steris Guides FY Adjusted EPS to $11.35-$11.55
STE sits 27% above its 52-week low of $195.14 on elevated volume (2.0× avg).
Summary
Steris issued full-year adjusted EPS guidance of $11.35 to $11.55. The range lands against a stock at $247.91 and a Q1 FY2027 base of $2.04 diluted EPS, up 14% year over year, so the midpoint implies continued double-digit growth. The company also reported second-quarter revenue of $1.6 billion and adjusted EPS of $2.94. The guidance follows the $2.1 billion cash deal for Xodus Medical announced in October, which carries up to $150 million in earnouts and will shape how much of the EPS range reflects organic versus acquired earnings.
At the time of this announcement, STE was trading at $247.91 on NYSE in the Life Sciences sector, with a market capitalization of approximately $24.2B. The 52-week trading range was $195.14 to $269.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.